# Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)

> **NCT02290613** · PHASE2 · COMPLETED · sponsor: **Heidelberg University** · enrollment: 38 (actual)

## Conditions studied

- Systemic Sclerosis
- Pulmonary Hypertension

## Interventions

- **DRUG:** Ambrisentan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02290613
- **Lead sponsor:** Heidelberg University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-01
- **Primary completion:** 2017-11-27
- **Final completion:** 2017-12-31
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02290613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02290613, "Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02290613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*